Cargando…
Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy
Diabetic nephropathy (DN), a severe microvascular complication of diabetes mellitus (DM), is the most common form of chronic kidney disease (CKD) and a leading cause of renal failure in end-stage renal disease. No currently available treatment can achieve complete cure. Traditional treatments have m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441178/ https://www.ncbi.nlm.nih.gov/pubmed/36068795 http://dx.doi.org/10.2147/DMSO.S380550 |
_version_ | 1784782519291346944 |
---|---|
author | Liu, Chunkang Wu, Kunzhe Gao, Huan Li, Jianyang Xu, Xiaohua |
author_facet | Liu, Chunkang Wu, Kunzhe Gao, Huan Li, Jianyang Xu, Xiaohua |
author_sort | Liu, Chunkang |
collection | PubMed |
description | Diabetic nephropathy (DN), a severe microvascular complication of diabetes mellitus (DM), is the most common form of chronic kidney disease (CKD) and a leading cause of renal failure in end-stage renal disease. No currently available treatment can achieve complete cure. Traditional treatments have many limitations, such as painful subcutaneous insulin injections, nephrotoxicity and hepatotoxicity with oral medication, and poor patient compliance with continual medication intake. Given the known drawbacks, recent research has suggested that nanoparticle-based drug delivery platforms as therapeutics may provide a promising strategy for treating debilitating diseases such as DN in the future. This administration method provides multiple advantages, such as delivering the loaded drug to the precise target of action and enabling early prevention of CKD progression. This article discusses the development of the main currently used nanoplatforms, such as liposomes, polymeric NPs, and inorganic NPs, as well as the prospects and drawbacks of nanoplatform application in the treatment of CKD. |
format | Online Article Text |
id | pubmed-9441178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94411782022-09-05 Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy Liu, Chunkang Wu, Kunzhe Gao, Huan Li, Jianyang Xu, Xiaohua Diabetes Metab Syndr Obes Review Diabetic nephropathy (DN), a severe microvascular complication of diabetes mellitus (DM), is the most common form of chronic kidney disease (CKD) and a leading cause of renal failure in end-stage renal disease. No currently available treatment can achieve complete cure. Traditional treatments have many limitations, such as painful subcutaneous insulin injections, nephrotoxicity and hepatotoxicity with oral medication, and poor patient compliance with continual medication intake. Given the known drawbacks, recent research has suggested that nanoparticle-based drug delivery platforms as therapeutics may provide a promising strategy for treating debilitating diseases such as DN in the future. This administration method provides multiple advantages, such as delivering the loaded drug to the precise target of action and enabling early prevention of CKD progression. This article discusses the development of the main currently used nanoplatforms, such as liposomes, polymeric NPs, and inorganic NPs, as well as the prospects and drawbacks of nanoplatform application in the treatment of CKD. Dove 2022-08-31 /pmc/articles/PMC9441178/ /pubmed/36068795 http://dx.doi.org/10.2147/DMSO.S380550 Text en © 2022 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liu, Chunkang Wu, Kunzhe Gao, Huan Li, Jianyang Xu, Xiaohua Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title | Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title_full | Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title_fullStr | Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title_full_unstemmed | Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title_short | Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy |
title_sort | current strategies and potential prospects for nanoparticle-mediated treatment of diabetic nephropathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441178/ https://www.ncbi.nlm.nih.gov/pubmed/36068795 http://dx.doi.org/10.2147/DMSO.S380550 |
work_keys_str_mv | AT liuchunkang currentstrategiesandpotentialprospectsfornanoparticlemediatedtreatmentofdiabeticnephropathy AT wukunzhe currentstrategiesandpotentialprospectsfornanoparticlemediatedtreatmentofdiabeticnephropathy AT gaohuan currentstrategiesandpotentialprospectsfornanoparticlemediatedtreatmentofdiabeticnephropathy AT lijianyang currentstrategiesandpotentialprospectsfornanoparticlemediatedtreatmentofdiabeticnephropathy AT xuxiaohua currentstrategiesandpotentialprospectsfornanoparticlemediatedtreatmentofdiabeticnephropathy |